NewslettersDermal Cell News FDA Delays BLA for Lifileucel in Patients with Advanced Melanoma By Laurisa Dohm - November 21, 2022 0 The FDA has delayed a biologics license application (BLA) for lifileucel, a treatment for unresectable or metastatic melanoma, until the start of 2023 due to a request for additional data on the agent. [Targeted Oncology] Press Release